Substance / Medication

Tasimelteon

Overview

Active Ingredient
tasimelteon
RxNorm CUI
1490468
Labeler: Apotex Corp.Updated: 2025-04-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger Damien, Quera-Salva Maria-Antonia, Vecchierini Marie-Françoise et al. · Expert Opin Drug Saf · 2015
PMID: 26393492Meta-Analysis
Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon.
Torres Rosarelis, Fisher Michaela, Birznieks Gunther et al. · J Sleep Res · 2022
PMID: 34152055RCTFull text (PMC)
Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study.
Smieszek Sandra P, Kaden Alyssa R, Johnson Caroline E et al. · Front Neurosci · 2023
PMID: 38033548Case ReportFull text (PMC)
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS.
Zuo Tianqi, Sun Shengzhu, Yang Jingya et al. · Expert Opin Drug Saf · 2025
PMID: 39928318Other
Protective effects of tasimelteon on kidney injury in a traumatic brain injury rat model: a histopathological and immunohistochemical study.
Milletsever Adem, Asci Halil, Taner Rumeysa et al. · Eur J Trauma Emerg Surg · 2025
PMID: 40576729OtherFull text (PMC)
Effects of Tasimelteon Treatment on Traumatic Brain Injury Through NRF-2/HO-1 and RIPK1/RIPK3/MLKL Pathways in Rats.
Özden Eyyüp Sabri, Özcan Mustafa Soner, Savran Mehtap et al. · Mol Neurobiol · 2025
PMID: 39878865PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tasimelteon (substance)
SNOMED CT
702394009
UMLS CUI
C1313052
RxNorm CUI
1490468
Labeler
Apotex Corp.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.